Pharmapark

Executive Summary

Pharmapark is a Moscow-based, full-cycle biotechnological company with over 20 years of experience in developing, manufacturing, and commercializing biologics and small molecules for serious diseases including cancer, hepatitis, and autoimmune disorders. The company operates from R&D through registration and commercialization, positioning itself as a vertically integrated player in the Russian and potentially broader Eurasian markets. Currently at Phase 3 stage, Pharmapark is advancing late-stage candidates, which implies near-term regulatory and clinical milestones. However, the company operates in a challenging geopolitical environment with limited visibility into its pipeline specifics and funding sources. Despite these risks, Pharmapark's long-standing presence and integrated model provide a foundation for potential value creation if its lead programs succeed. The company's conviction score is moderate, reflecting the balance between late-stage opportunities and execution uncertainties.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 trial results for lead biologic candidate (oncology/immunology)50% success
• Q2 2027Regulatory submission in Russia or Eurasian Economic Union for a small molecule drug60% success
• Q3 2026Partnership or licensing deal with a Western or Asian pharmaceutical company30% success